Patents by Inventor Chetana Rao-Naik

Chetana Rao-Naik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190055321
    Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.
    Type: Application
    Filed: August 14, 2018
    Publication date: February 21, 2019
    Inventors: Stanley R. Krystek, JR., Yong Zhang, Gregory D. Vite, Arvind Rajpal, Chetana Rao-Naik, Paul E. Morin, Mohan Srinivasan, Zheng Lin, Virginie Lafont, Alla Pritsker
  • Publication number: 20180362619
    Abstract: Variant antibodies having cysteine substitutions at selected positions in the Fc region can be conjugated via the thiol group of the substituted-in cysteine.
    Type: Application
    Filed: December 20, 2016
    Publication date: December 20, 2018
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Paul O. SHEPPARD, Henrik ANDERSEN, Xiang SHAO, Chetana RAO-NAIK, Arvind RAJPAL
  • Publication number: 20180282712
    Abstract: A variant transglutaminase having increased specific activity compared to wild-type Streptomyces mobaraensis transglutaminase can be used for conjugating proteins.
    Type: Application
    Filed: September 30, 2016
    Publication date: October 4, 2018
    Inventor: Chetana RAO-NAIK
  • Publication number: 20180265851
    Abstract: Transglutaminase variants capable of conjugating an antibody that is not conjugated by wild-type transglutaminase from Streptomyces mobaraensis.
    Type: Application
    Filed: September 30, 2016
    Publication date: September 20, 2018
    Inventors: Chetana RAO-NAIK, Ganapathy N. SARMA, Akbar NAYEEM
  • Patent number: 9932411
    Abstract: The invention provides antibodies which bind to the extracellular domain of the Tyrosine-protein kinase transmembrane receptor Matriptase. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of cancer, including gastric cancer, colorectal cancer, prostate cancer, breast cancer, ovarian cancer lung cancer, preferably SCLC, esophageal cancer, head and neck cancer, pancreatic cancer, lymphoma preferably non-Hodgkin's lymphoma and skin cancer.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: April 3, 2018
    Assignee: Oxford BioTherapeutics Ltd
    Inventors: Jonathan Alexander Terrett, Chetana Rao-Naik, Haichun Huang, Sarah Pogue, Erika Meaddough, Michelle Kuhne, Chin Pan
  • Publication number: 20180037921
    Abstract: An antibody has at a heavy chain thereof a C-terminal extension that includes at least one glutamine that is a substrate for transglutaminase, enabling the transglutaminase-mediated preparation antibody-drug conjugates using such antibody.
    Type: Application
    Filed: March 1, 2016
    Publication date: February 8, 2018
    Inventors: Chetana RAO-NAIK, Shrikant DESHPANDE
  • Publication number: 20170326249
    Abstract: An antibody-drug conjugate having a structure represented by formula (I) wherein m is 1, 2, 3, or 4 and Ab is an anti-glypican-3 antibody having heavy and light chain CDRs as disclosed herein.
    Type: Application
    Filed: May 5, 2017
    Publication date: November 16, 2017
    Inventors: Chin PAN, Josephine M. CARDARELLI, Haichun HUANG, Sanjeev GANGWAR, Qiang CONG, Karla A. HENNING, Chetana RAO-NAIK, Mohan SRINIVASAN, Vangipuram S. RANGAN, Francis Y. LEE, Ginger C. RAKESTRAW
  • Publication number: 20170058031
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.
    Type: Application
    Filed: November 10, 2016
    Publication date: March 2, 2017
    Inventors: David John King, Alison WITTE, Heidi N. LEBLANC, Richard THEOLIS, Asna MASOOD, Mark YAMANAKA, Kyra D. ZENS, Sarah R. REED, Tim SPROUL, Chetana RAO-NAIK, David Passmore, Dawn M. TANAMACHI, Kristopher TOY
  • Patent number: 9499632
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.
    Type: Grant
    Filed: February 20, 2013
    Date of Patent: November 22, 2016
    Assignee: E.R. Squibb & Sons, L.L.C.
    Inventors: David John King, Alison Witte, Heidi N. Leblanc, Richard Theolis, Asna Masood, Mark Yamanaka, Kyra D. Zens, Sarah R. Reed, Tim Sproul, Chetana Rao-Naik, David Passmore, Dawn M. Tanamachi, Kristopher Toy
  • Publication number: 20160289338
    Abstract: The invention provides antibodies which bind to the extracellular domain of the Tyrosine-protein kinase transmembrane receptor Matriptase. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of cancer, including gastric cancer, colorectal cancer, prostate cancer, breast cancer, ovarian cancer lung cancer, preferably SCLC, esophageal cancer, head and neck cancer, pancreatic cancer, lymphoma preferably non-Hodgkin's lymphoma and skin cancer.
    Type: Application
    Filed: November 25, 2014
    Publication date: October 6, 2016
    Inventors: Jonathan Alexander TERRETT, Chetana RAO-NAIK, Haichun HUANG, Sarah POGUE, Erika MEADDOUGH, Michelle KUHNE, Chin PAN
  • Publication number: 20130230530
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.
    Type: Application
    Filed: February 20, 2013
    Publication date: September 5, 2013
    Applicant: Medarex, Inc.
    Inventors: David John King, Alison Witte, Heidi N. Leblanc, Richard Theolis, Asna Masood, Mark Yamanaka, Kyra D. Zens, Sarah R. Reed, Tim Sproul, Chetana Rao-Naik, David Passmore, Dawn M. Tanamachi, Kristopher Toy
  • Patent number: 8481683
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: July 9, 2013
    Assignee: Medarex, Inc.
    Inventors: David John King, Alison Witte, Heidi N. LeBlanc, Richard Theolis, Asna Masood, Mark Yamanaka, Kyra D. Zens, Sarah R. Reed, Tim Sproul, Chetana Rao-Naik, David Passmore, Dawn M. Tanamachi, Kristopher Toy
  • Patent number: 8425904
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: April 23, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jonathan A. Terrett, Sarah L. Pogue, Kristopher Toy, Lan Yang, Chetana Rao-Naik, Bingliang Chen
  • Patent number: 8420084
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, more particularly engineered antibodies resulting in increased binding to Fc receptors and/or increased potency for ADCC or immunoconjugates, which specifically bind to CADM1 with high affinity. Nucleic acid molecules encoding CADM1 antibodies, expression vectors, host cells and methods for expressing the CADM1 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CADM1 antibodies are also provided. Methods for detecting CADM1, as well as methods for treating various cancers, including lung cancer and pancreatic cancer, are disclosed.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: April 16, 2013
    Assignees: Medarex, Inc., Oxford BioTherapeutics Ltd
    Inventors: Jonathan Alexander Terrett, Heidi Leblanc, Haichun Huang, Erika Meaddough, Chin Pan, Bingliang Chen, Chetana Rao-Naik
  • Patent number: 8399623
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: March 19, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jonathan A. Terrett, Sarah L. Pogue, Kristopher Toy, Lan Yang, Chetana Rao-Naik, Bingliang Chen
  • Patent number: 8383779
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: February 26, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jonathan A. Terrett, Sarah L. Pogue, Kristopher Toy, Lan Yang, Chetana Rao-Naik, Bingliang Chen
  • Publication number: 20130028905
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided.
    Type: Application
    Filed: August 16, 2012
    Publication date: January 31, 2013
    Inventors: Jonathan A. Terrett, Sarah L. Pogue, Kristopher Toy, Lan Yang, Chetana Rao-Naik, Bingliang Chen
  • Publication number: 20130028906
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided.
    Type: Application
    Filed: August 16, 2012
    Publication date: January 31, 2013
    Inventors: Jonathan A. Terrett, Sarah L. Pogue, Kristopher Toy, Lan Yang, Chetana Rao-Naik, Bingliang Chen
  • Publication number: 20130028904
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided.
    Type: Application
    Filed: August 16, 2012
    Publication date: January 31, 2013
    Inventors: Jonathan A. Terrett, Sarah L. Pogue, Kristopher Toy, Lan Yang, Chetana Rao-Naik, Bingliang Chen
  • Patent number: 8268970
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided.
    Type: Grant
    Filed: September 29, 2008
    Date of Patent: September 18, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jonathan A. Terrett, Sarah L. Pogue, Kristopher Toy, Lan Yang, Chetana Rao-Naik, Bingliang Chen